Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference20 articles.
1. Kuroda T, Kumagi T, Yokota T, Seike H, Nishiyama M, Imai Y, Inada N, Shibata N, Imamine S, Okada S, Koizumi M, Yamanishi H, Azemoto N, Miyaike J, Tanaka Y, Tatsukawa H, Utsunomiya H, Ohno Y, Miyake T, Hirooka M, Furukawa S, Abe M, Ikeda Y, Matsuura B, Hiasa Y, Onji M, EPOCH Study Group (2013) Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients. BMC Gastroenterol 13:134. https://doi.org/10.1186/1471-230X-13-134
2. Heinemann V (2002) Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 29(Supplement 20):9–16. https://doi.org/10.1053/sonc.2002.37372
3. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277. https://doi.org/10.1001/jama.297.3.267
4. Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B (2009) Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 35:600–604. https://doi.org/10.1016/j.ejso.2008.12.006
5. Ministry of Health, Labour and Welfare (2018) [Center for Cancer Control and Information Services, National Cancer Center, Japan web site]. Vital Stat Jpn. https://ganjoho.jp/reg_stat/statistics/dl/index.html#mortality. Accessed 26 Nov 2020
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献